Press Releases

Biophytis Identifies False Report Regarding COVA Study

Biophytis gives updates on its Phase 2-3 COVA study on COVID-19

Judgment of the Paris Commercial Court of March 16, 2021 in the case of Biophytis against Negma Group Ltd

Biophytis AGM meeting will take place on April 26, 2021

Biophytis Reports 2020 Full Year Results

Biophytis Announces Expansion of Patient Recruitment for Part 2 of the Phase 2-3 COVA Trial (“COVA Study”) following Regulatory Authorities approvals in France and Belgium

Biophytis Announces Closing of ADS Offering on Nasdaq Capital Market

Biophytis Announces Pricing of $20.1 Million U.S. Initial Public Offering of American Depositary Shares and Approval to List on Nasdaq Capital Market

Biophytis Announces Temporary Trading Halt of its Shares and Share Warrants on Euronext Growth

Biophytis Announces Trading Resumption of its Ordinary Shares and Share Warrants on Euronext